Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Urogen Pharma ( (URGN) ) has shared an announcement.
On February 26, 2026, UroGen Pharma Ltd. and its U.S. subsidiary entered into a new loan agreement with BioPharma Credit-affiliated lenders for term loans of up to $250 million, comprising a $200 million Tranche A funded at closing and a $50 million Tranche B available at the company’s option through June 30, 2027. The Tranche A proceeds refinance an existing $125 million term facility and provide additional capital for general corporate and working capital needs, with the debt maturing five years after the initial closing and carrying a fixed 8.25% annual interest rate, back-ended principal amortization beginning in 2030, and customary fees, security interests, covenants and default provisions that tighten operational flexibility but remove financial covenants and extend the company’s funding runway.
The loan is secured by substantially all tangible and intangible assets of UroGen and its borrower subsidiary, including intellectual property, and restricts asset sales, incurrence of new debt, dividend payments and certain change-of-control transactions without lender consent. While the structure enhances balance-sheet liquidity and pushes out principal repayments, it also introduces prepayment fees, makewhole costs on early repayment and mandatory prepayment triggers on change of control or certain debt actions, underscoring lenders’ priority on capital protection and influencing the company’s future strategic and financing options.
The most recent analyst rating on (URGN) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Urogen Pharma stock, see the URGN Stock Forecast page.
Spark’s Take on URGN Stock
According to Spark, TipRanks’ AI Analyst, URGN is a Neutral.
Urogen Pharma’s overall stock score is driven by significant financial challenges, including negative profitability and high leverage, which weigh heavily on the score. Positive technical indicators and promising product developments provide some balance, but valuation concerns and operational challenges remain significant risks.
To see Spark’s full report on URGN stock, click here.
More about Urogen Pharma
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing therapies for uro-oncology and specialty cancers, with operations conducted through its U.S. subsidiary UroGen Pharma, Inc. The company targets urologic and urothelial diseases, leveraging proprietary drug delivery technologies and related intellectual property as key assets in its business model.
Average Trading Volume: 744,536
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
See more insights into URGN stock on TipRanks’ Stock Analysis page.